How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we investigated differences in QTcF among participants in the three interventional arms: BPaL (bedaquiline, pretomanid, an...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Antimicrobial agents and chemotherapy Ročník 68; číslo 7; s. e0053624
Hlavní autoři:	Motta, Ilaria, Cusinato, Martina, Ludman, Andrew J, Lachenal, Nathalie, Dodd, Matthew, Soe, Moe, Abdrasuliev, Tleubergen, Usmanova, Ruzilya, Butabekov, Ilhomjon, Nikolaevna, Tigay Zinaida, Liverko, Irina, Parpieva, Nargiza, Moodliar, Ronelle, Solodovnikova, Varvara, Kazounis, Emil, Nyang'wa, Bern-Thomas, Fielding, Katherine L, Berry, Catherine
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 09.07.2024
Témata:	Adult Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Clofazimine - adverse effects Clofazimine - therapeutic use Diarylquinolines - adverse effects Diarylquinolines - therapeutic use Electrocardiography Female Humans Long QT Syndrome - chemically induced Male Middle Aged Moxifloxacin - adverse effects Moxifloxacin - therapeutic use Republic of Belarus Rifampin - adverse effects Rifampin - therapeutic use South Africa Tuberculosis, Multidrug-Resistant - drug therapy South Africa Republic of Belarus DR-TB cardiotoxicity BPaL/M bedaquiline drug-resistant tuberculosis
ISSN:	1098-6596, 1098-6596
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!